Profil bibliographique

Joyson Karakunnel

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

51Publications signalées

2092Citations signalées

2Affiliations récentes

Institutions déclarées

Parker Institute for Cancer Immunotherapy Innate Pharma (France)

Domaines associés

Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchPancreatic and Hepatic Oncology ResearchLung Cancer Treatments and MutationsImmunotherapy and Immune Responses

Publications récentes

Accès ouvert 2022 articleOpenAlex

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*

Julien Carvelli, Ferhat Meziani, Jean Dellamonica, Pierre‐Yves Cordier et autres

29 citationsCritical Care Medicine

Accès ouvert 2022 articleOpenAlex

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara, Eileen M. O’Reilly et autres

374 citationsNature Medicine

2022 conference-abstractOpenAlex

Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.

Jaclyn P. Lyman, Abigail Doucette, Binbin Zheng-Lin, Christopher R. Cabanski et autres

5 citationsJournal of Clinical Oncology

Accès ouvert 2022 articleOpenAlex

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Claire F. Friedman, Christine N. Spencer, Christopher R. Cabanski, Katherine S. Panageas et autres

45 citationsJournal for ImmunoTherapy of Cancer

Accès ouvert 2022 preprintOpenAlex

Avdoralimab (anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FORCE)

Julien Carvelli, Ferhat Meziani, Jean Dellamonica, Pierre‐Yves Cordier et autres

0 citationsSSRN Electronic Journal

2021 conference-abstractOpenAlex

Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

Mark H. O’Hara, Eileen M. O’Reilly, Robert A. Wolff, Zev A. Wainberg et autres

24 citationsJournal of Clinical Oncology

2020 articleOpenAlex

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, Robert A. Wolff et autres

308 citationsThe Lancet Oncology

Accès ouvert 2019 articleOpenAlex

Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies

John D. Powderly, Alexander I. Spira, Rafael Selgas Gutiérrez, Daniel DiRenzo et autres

20 citationsAnnals of Oncology

Accès ouvert 2019 articleOpenAlex

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Jeffrey R. Infante, Sanjay Goel, H. Burris, Chelsea Black et autres

31 citationsJournal for ImmunoTherapy of Cancer

2019 conference-abstractOpenAlex

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

John D. Powderly, Paul L. de Souza, Rodolfo Gutierrez, Lisa G. Horvath et autres

32 citationsJournal of Clinical Oncology

Accès ouvert 2019 datasetOpenAlex

Additional file 1: of Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Aung Naing, Jeffrey R. Infante, Sanjay Goel, Howard A. Burris et autres

0 citationsFigshare

2018 articleOpenAlex

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

Lisa Seitz, Lixia Jin, Manmohan R. Leleti, Devika Ashok et autres

68 citationsInvestigational New Drugs

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.